Since its establishment in 1998, the company has focused on the high-end pharmaceutical lipid excipients sector, leveraging technological innovation to overcome industry “bottleneck” challenges. It pioneered integrated green production technologies, achieving domestic production of core products such as refined egg yolk phosphatidylcholine for injection and refined olive oil, thereby significantly boosting the localization rate of domestic pharmaceutical lipid excipients.

The company operates several research platforms, including the National Engineering Research Center for Traditional Chinese Medicine Pharmaceutical Process Technology and New Drug Creation, and the Guangdong Provincial Key Laboratory of Pharmaceutical Lipids. It has accumulated over 240 patents, with its products certified by authoritative agencies in multiple countries, including the EU and the United States, and exported to more than 20 countries worldwide, serving over a thousand domestic and international clients such as AstraZeneca and B. Braun Group.

Based in Guangzhou and radiating globally, Baiyunshan Hanfang, with its full-chain industrial layout and robust R&D capabilities, continuously provides domestically produced, safe, and reliable high-end pharmaceutical excipients to the pharmaceutical industry, contributing to the modernization of traditional Chinese medicine and the global health cause.